Parkman Healthcare Partners’s Entera Bio ENTX Stock Holding History

Parkman Healthcare Partners’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$320K	Buy	288,670 +13,597	+5%	+$19.1K	0.03%	90
2025 Q4	$534K	Sell	275,073 -5,749	-2%	-$13.5K	0.05%	96
2025 Q3	$539K	Sell	280,822 -75,000	-21%	-$144K	0.06%	89
2025 Q2	$676K	Sell	355,822 -83,810	-19%	-$166K	0.08%	87
2025 Q1	$747K	Buy	439,632 +25,900	+6%	+$56.4K	0.09%	86
2024 Q4	$877K	Buy	413,732 +2,656	+0.6%	+$4.96K	0.12%	85
2024 Q3	$781K	Buy	411,076 +9,558	+2%	+$17K	0.1%	87
2024 Q2	$739K	Buy	+401,518	New	+$879K	0.1%	83

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

SEIA

Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Parkman Healthcare Partners's ENTX Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Entera Bio (ENTX) stake by 4.9% in Q1 2026, buying an estimated $19.1K and bringing the position to 288,670 shares worth $320K. The position accounts for 0.03% of the portfolio, ranked #90.

Parkman Healthcare Partners first reported a position in ENTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $877K in Q4 2024. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

Parkman Healthcare Partners held 288,670 shares of Entera Bio worth $320K as of Q1 2026.
Parkman Healthcare Partners bought 13,597 Entera Bio shares in Q1 2026, an estimated $19.1K.
Entera Bio made up 0.03% of Parkman Healthcare Partners's portfolio in Q1 2026, its #90 holding.
Parkman Healthcare Partners first reported a position in Entera Bio in Q2 2024 and has held it in 8 quarters since.
Parkman Healthcare Partners's Entera Bio position peaked at $877K in Q4 2024.
26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.